News
VPTDF
0.082
NaN%
--
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 1d ago
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 2d ago
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 02/20 14:18
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 02/12 13:20
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 01/28 10:05
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 01/19 10:44
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 01/16 12:35
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 01/08 11:52
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 12/18/2025 05:35
Stocks in play: Ventripoint Diagnostics Ltd
Barchart · 12/12/2025 09:04
Ventripoint Diagnostics appoints David Swetlow as CFO
Seeking Alpha · 12/03/2025 13:57
Weekly Report: what happened at VPTDF last week (0908-0912)?
Weekly Report · 09/15/2025 10:55
Weekly Report: what happened at VPTDF last week (0901-0905)?
Weekly Report · 09/08/2025 10:57
Weekly Report: what happened at VPTDF last week (0825-0829)?
Weekly Report · 09/01/2025 10:53
Weekly Report: what happened at VPTDF last week (0818-0822)?
Weekly Report · 08/25/2025 11:02
Weekly Report: what happened at VPTDF last week (0811-0815)?
Weekly Report · 08/18/2025 10:55
Weekly Report: what happened at VPTDF last week (0804-0808)?
Weekly Report · 08/11/2025 11:01
Weekly Report: what happened at VPTDF last week (0728-0801)?
Weekly Report · 08/04/2025 11:03
Weekly Report: what happened at VPTDF last week (0721-0725)?
Weekly Report · 07/28/2025 11:04
Weekly Report: what happened at VPTDF last week (0714-0718)?
Weekly Report · 07/21/2025 10:55
More
Webull provides a variety of real-time VPTDF stock news. You can receive the latest news about Ventripoint Diagnostics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About VPTDF
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.